Enter your email address
Submit
Write your message
Volume 18, Issue 3 (Iranian Journal of Breast Diseases 2025)
ijbd 2025, 18(3): 100-111 |
Back to browse issues page
Ethics code: IR.KAUMS.REC.1404.006
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
TaheriAkerdi M, Rezvani Z, dowlati M. Genetic Mutations in Breast Cancer: Implications for Prognostic Assessment and Risk Stratification - A Case Report. ijbd 2025; 18 (3) :100-111
URL: http://ijbd.ir/article-1-1168-en.html
URL: http://ijbd.ir/article-1-1168-en.html
1- Department of Cell and Molecular Biology, Faculty of Chemistry, University of Kashan, Kashan, Iran
2- Department of Cell and Molecular Biology, Faculty of Chemistry, University of Kashan, Kashan, Iran ,rezvani@kashanu.ac.ir
3- Department of Medical Genetics, Kashan University of Medical Sciences and Health Services, Kashan, Iran
2- Department of Cell and Molecular Biology, Faculty of Chemistry, University of Kashan, Kashan, Iran ,
3- Department of Medical Genetics, Kashan University of Medical Sciences and Health Services, Kashan, Iran
Abstract: (1041 Views)
Introduction: Genetic mutations play a crucial role in breast cancer pathogenesis. While BRCA1/2 mutations are well-characterized, rare variants in other genes with moderate-to-low penetrance may also contribute to hereditary breast cancer risk, particularly in early-onset cases.
Case Presentation: A 38-year-old woman with invasive ductal carcinoma and axillary lymph node metastasis, with a strong family history of breast and prostate cancer, underwent whole-exome sequencing (WES).
Findings: WES identified a likely pathogenic frameshift mutation in SAMD9, predicted to disrupt tumor suppression, and two variants of uncertain significance (VUS) in TTK and BRAF.
Conclusion:This case underscores the value of WES in identifying rare variants for personalized risk assessment, targeted surveillance, and potential family screening in early-onset and familial breast cancer. Identification of rare variants can facilitate personalized risk assessment and guide clinical management.
Case Presentation: A 38-year-old woman with invasive ductal carcinoma and axillary lymph node metastasis, with a strong family history of breast and prostate cancer, underwent whole-exome sequencing (WES).
Findings: WES identified a likely pathogenic frameshift mutation in SAMD9, predicted to disrupt tumor suppression, and two variants of uncertain significance (VUS) in TTK and BRAF.
Conclusion:This case underscores the value of WES in identifying rare variants for personalized risk assessment, targeted surveillance, and potential family screening in early-onset and familial breast cancer. Identification of rare variants can facilitate personalized risk assessment and guide clinical management.
Keywords: Breast Cancer, Case Report, Genetic Mutation, SAMD9, TTK, BRAF, Hereditary Cancer, Whole-Exome Sequencing
Type of Study: case report |
Subject:
molecular cell
Received: 2025/01/30 | Accepted: 2025/04/29 | Published: 2025/09/1
Received: 2025/01/30 | Accepted: 2025/04/29 | Published: 2025/09/1
References
1. Terpstra A, West CE, Fennis J, Schouten J, Van der Veen E. Hypocholesterolemic effect of dietary soy protein versus casein in rhesus monkeys (Macaca mulatta). The American Journal of Clinical Nutrition. 1984;39(1):1-7. doi:10.1093/ajcn/39.1.1 [DOI:10.1093/ajcn/39.1.1] [PMID]
2. Subaşıoğlu A, Güç ZG, Gür EÖ, Tekindal MA, Atahan MK. Genetic, surgical and oncological approach to breast cancer, with BRCA1, BRCA2, CDH1, PALB2, PTEN and TP53 variants. European Journal of Breast Health. 2023;19(1):55. doi:10.4274/ejbh.galenos.2022.2022-7-2 [DOI:10.4274/ejbh.galenos.2022.2022-7-2] [PMID] []
3. Yiallourou A. Hereditary Breast Cancer Syndromes Breast cancer represents the most common type of cancer affect-ing the female population worldwide. According to the most recent data from the Global Cancer Observatory (GLOBOCAN), breast cancer has surpassed lung cancer as the leading cause of. Breast Cancer Management for Surgeons: An Examination Guide. 2023:79. DOI:10.1111/his.14808 [DOI:10.1111/his.14808] [PMID] []
4. chek n, rad51c rd. Germline genetic testing for gene variants associated with breast cancer in individuals at moderate and high breast cancer risk (e.g., chek2, atm, bard1, etc.). doi:10.1016/j.breast.2022.06.003 [DOI:10.1016/j.breast.2022.06.003] [PMID] []
5. Imyanitov EN, Kuligina ES, Sokolenko AP, Suspitsin EN, Yanus GA, Iyevleva AG, et al. Hereditary cancer syndromes. World Journal of Clinical Oncology. 2023;14(2):40. doi: 10.5306/wjco.v14.i2.40 [DOI:10.5306/wjco.v14.i2.40] [PMID] []
6. Elengoe A. A Short Review on Breast Cancer: A Short Review on Breast Cancer. International Journal of Biotechnology and Biomedicine (IJBB). 2024;1(1):1-11. doi:10.31674/ijbb.2024.v01i01.001 [DOI:10.31674/ijbb.2024.v01i01.001]
7. Huang Y, Qiu Y, Ding L, Ren S, Jiang Y, Luo J, et al. Somatic mutations in four novel genes contribute to homologous recombination deficiency in breast cancer: a real‐world clinical tumor sequencing study. The Journal of Pathology: Clinical Research. 2024;10(2):e12367. doi: 10.1002/2056-4538.12367. [DOI:10.1002/2056-4538.12367] [PMID] []
8. Kiecolt-Glaser JK, Bane C, Glaser R, Malarkey WB. Love, marriage, and divorce: newlyweds' stress hormones foreshadow relationship changes. Journal of consulting and clinical psychology. 2003;71(1):176. doi:10.1037/0022-006X.71.1.176. [DOI:10.1037/0022-006X.71.1.176] [PMID]
9. Sorokowski P, Żelaźniewicz A, Nowak J, Groyecka A, Kaleta M, Lech W, et al. Romantic love and reproductive hormones in women. International Journal of Environmental Research and Public Health. 2019;16(21):4224. doi10.3390/ijerph16214224. [DOI:10.3390/ijerph16214224] [PMID] []
10. Marazziti D, Canale D. Hormonal changes when falling in love. Psychoneuroendocrinology. 2004;29(7):931-6. doi: 10.1016/j.psyneuen.2003.08.006. [DOI:10.1016/j.psyneuen.2003.08.006] [PMID]
11. Inaba T, Nagamachi A. Revertant somatic mosaicism as a cause of cancer. Cancer Science. 2021;112(4):1383-9. doi:10.1111/cas.14852. [DOI:10.1111/cas.14852] [PMID] []
12. Rivera-Rivera Y, Vargas G, Jaiswal N, Núñez-Marrero A, Li J, Chen D-T, et al. Ethnic and racial-specific differences in levels of centrosome-associated mitotic kinases, proliferative and epithelial-to-mesenchymal markers in breast cancers. Cell Division. 2022;17(1):6. doi:10.1186/s13008-022-00082-3. [DOI:10.1186/s13008-022-00082-3] [PMID] []
13. Owsley J, Stein MK, Porter J, In GK, Salem M, O'Day S, et al. Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database. Experimental Biology and Medicine. 2021;246(1):31-9. doi: 10.1177/1535370220959657. [DOI:10.1177/1535370220959657] [PMID] []
14. Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. Cancers. 2021;13(17):4287. doi: 10.3390/cancers13174287. [DOI:10.3390/cancers13174287] [PMID] []
15. Wong JC, Bryant V, Lamprecht T, Ma J, Walsh M, Schwartz J, et al. Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes. JCI insight. 2018;3(14):e121086. doi:10.1172/jci.insight.121086. [DOI:10.1172/jci.insight.121086] [PMID] []
16. Hershkovitz D, Gross Y, Nahum S, Yehezkel S, Sarig O, Uitto J, et al. Functional characterization of SAMD9, a protein deficient in normophosphatemic familial tumoral calcinosis. Journal of Investigative Dermatology. 2011;131(3):662-9. doi: 10.1038/jid.2010.387. [DOI:10.1038/jid.2010.387] [PMID] []
17. Tsai Y-M, Wu K-L, Chang Y-Y, Hung J-Y, Chang W-A, Chang C-Y, et al. Upregulation of Thr/Tyr kinase increases the cancer progression by neurotensin and dihydropyrimidinase-like 3 in lung cancer. International Journal of Molecular Sciences. 2020;21(5):1640. doi:10.3390/ijms21051640. [DOI:10.3390/ijms21051640] [PMID] []
18. Niittymäki I, Gylfe A, Laine L, Laakso M, Lehtonen HJ, Kondelin J, et al. High frequency of TTK mutations in microsatellite-unstable colorectal cancer and evaluation of their effect on spindle assembly checkpoint. Carcinogenesis. 2011;32(3):305-11. doi: 10.1093/carcin/bgq272. [DOI:10.1093/carcin/bgq272] [PMID]
19. Castellani G, Buccarelli M, Arasi MB, Rossi S, Pisanu ME, Bellenghi M, et al. BRAF mutations in melanoma: biological aspects, therapeutic implications, and circulating biomarkers. Cancers. 2023;15(16):4026. doi:10.3390/cancers15164026. [DOI:10.3390/cancers15164026] [PMID] []
20. Thiel A, Ristimäki A. Toward a molecular classification of colorectal cancer: the role of BRAF. Frontiers in oncology. 2013;3:281. doi:10.3389/fonc.2013.00281. [DOI:10.3389/fonc.2013.00281] [PMID] []
21. Henke LE, Pfeifer JD, Ma C, Perkins SM, DeWees T, El‐Mofty S, et al. BRAF mutation is not predictive of long‐term outcome in papillary thyroid carcinoma. Cancer medicine. 2015;4(6):791-9. doi:10.1002/cam4.417. [DOI:10.1002/cam4.417] [PMID] []
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
